Jazz Pharmaceuticals (JAZZ) Cost of Revenue (2010 - 2026)

Jazz Pharmaceuticals' Cost of Revenue history runs 17 years deep, the most recent figure standing at $134.1 million for Q1 2026.

• On a quarterly basis, Cost of Revenue rose 28.2% year-over-year to $134.1 million in Q1 2026; TTM through Mar 2026 was $532.8 million, a 17.14% increase from a year earlier, with the FY2025 full-year figure at $503.3 million, up 12.92% from the prior year.
• Cost of Revenue retreated to $134.1 million in Q1 2026 per JAZZ's latest filing, from $153.5 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $167.4 million in Q4 2022 and bottomed at $95.5 million in Q1 2024.
• The 5-year median for Cost of Revenue is $116.3 million (2025), against an average of $121.1 million.
• Across the five-year window, Cost of Revenue soared 186.85% in 2022 and tumbled 35.92% in 2023, its largest moves.
• Year by year, Cost of Revenue stood at $167.4 million in 2022, then slumped by 35.92% to $107.2 million in 2023, then advanced by 20.02% to $128.7 million in 2024, then grew by 19.28% to $153.5 million in 2025, then slipped by 12.65% to $134.1 million in 2026.
• Per Business Quant, the three latest JAZZ Cost of Revenue figures stand at $134.1 million (Q1 2026), $153.5 million (Q4 2025), and $128.9 million (Q3 2025).